Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)

Phase 3

Alcon Research (ALC)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Glaucoma

ALCOX.PANCX 470

View Full Landscape

Drug Information

Target Indication

Glaucoma

Clinical Trial

NCT00333125

Last updated: 12/24/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/23/2006

DuoTrav

Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Ophthalmic Goods•Europe•NASDAQ

Related Pipeline

Ofloxacin otic solutionPhase 3

Acute Otitis Media

Difluprednate 0.05% ophthalmic emulsionPhase 3

Endogenous Anterior Uveitis

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Phase 3

Allergic Conjunctivitis

AL-4943A ophthalmic solutionPhase 3

Allergic Conjunctivitis

Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solutionPhase 3

Glaucoma, Open-angle

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts